Swiss - Delayed Quote • CHF
Roche Holding AG (ROG.SW)
At close: April 26 at 5:31 PM GMT+2
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 20 | 20 |
| Avg. Estimate | 0 | 0 | 17.92 | 19.76 |
| Low Estimate | 0 | 0 | 17.35 | 18.65 |
| High Estimate | 0 | 0 | 18.95 | 20.97 |
| Year Ago EPS | -- | -- | 18.57 | 17.92 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 20 | 20 |
| Avg. Estimate | -- | -- | 60.69B | 64.22B |
| Low Estimate | -- | -- | 58.74B | 61.24B |
| High Estimate | -- | -- | 62.8B | 66.65B |
| Year Ago Sales | -- | -- | 58.72B | 60.69B |
| Sales Growth (year/est) | -- | -- | 3.40% | 5.80% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 17.92 | 19.76 |
| 7 Days Ago | 0 | 0 | 18.07 | 19.81 |
| 30 Days Ago | 0 | 0 | 18 | 19.71 |
| 60 Days Ago | 0 | 0 | 18.09 | 19.85 |
| 90 Days Ago | 0 | 0 | 19.18 | 21.04 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 4 | 5 |
| Up Last 30 Days | -- | -- | 8 | 9 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 7 | 5 |
Growth Estimates
| CURRENCY IN USD | ROG.SW | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 6.50% |
| Next Qtr. | -- | -- | -- | 12.00% |
| Current Year | -3.50% | -- | -- | 5.30% |
| Next Year | 10.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 4.25% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -0.90% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker
Related Tickers
NOVN.SW Novartis AG
89.50
-0.56%
BAYN.DE Bayer Aktiengesellschaft
27.40
+1.88%
SAN.PA Sanofi
91.23
-0.43%
NVS Novartis AG
97.44
-1.64%
SNY Sanofi
49.13
-0.47%
AZN.L AstraZeneca PLC
11,988.00
-0.32%
AZN AstraZeneca PLC
75.17
+0.19%
GSK.L GSK plc
1,653.00
+0.76%
BIIB Biogen Inc.
208.90
+3.18%
BMY Bristol-Myers Squibb Company
44.85
+0.34%